United States v. Paul Ono, United States of America v. Benjamin Langshaw

997 F.2d 647, 93 Cal. Daily Op. Serv. 5038, 93 Daily Journal DAR 8543, 1993 U.S. App. LEXIS 15983, 1993 WL 232175
CourtCourt of Appeals for the Ninth Circuit
DecidedJuly 1, 1993
Docket91-50718, 91-50725
StatusPublished
Cited by13 cases

This text of 997 F.2d 647 (United States v. Paul Ono, United States of America v. Benjamin Langshaw) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Paul Ono, United States of America v. Benjamin Langshaw, 997 F.2d 647, 93 Cal. Daily Op. Serv. 5038, 93 Daily Journal DAR 8543, 1993 U.S. App. LEXIS 15983, 1993 WL 232175 (9th Cir. 1993).

Opinion

SCHROEDER, Circuit Judge:

For the second time, Appellants Paul Ono and Benjamin Langshaw appeal their sentences imposed after being convicted for conspiracy to manufacture a controlled substance analogue and procuring the manufacture of a controlled substance analogue. In the Ono appeal we are now presented with a question left open in Ono’s earlier appeal and relating to reliance on the potency of the drug for sentencing purposes. United States v. Ono, 918 F.2d 1462 (9th Cir.1990) (“Ono I”). We affirm the sentences as to both appellants.

Both convictions were based on the appellants’ scheme to produce a designer drug known as OPP/PPP, which is chemically similar to heroin but more powerful. OPP/PPP is not a listed drug in the Sentencing Guidelines. The chemical analogue drug that is listed in the drug equivalency tables of the Guidelines is MPPP, although evidence in the *649 record indicates that OPP/PPP is more potent than MPPP. Id. at 1466.

The Ono Appeal

We reversed Ono’s original 240-month sentence because we held that the district court improperly used a multiplying factor to calculate the base offense level. Id. The multiplier was based on the potency of OPP/ PPP in relation to MPPP. We held that the Guidelines required the district court to compare OPP/PPP to a listed drug to determine the base offense level. “By applying a multiplying factor to account for OPP/PPP’s greater potency, the district court disregarded MPPP as the applicable scheduled and listed drug and considered properties of a chemical not listed in the statute, the Regulations, or the Guidelines; ... [t]his was error, as the district court’s task is to compare the synthetic drug to a listed drug under the Guidelines for the purposes of determining a defendant’s base offense level.” Ono I, 918 F.2d at 1467 (emphasis in original).

In so holding, however, we expressly left open the question of whether the potency considerations that prompted the district court to use the multiplier could serve as the basis for an upward departure from the sentencing ranges applicable to the offense. Id. See U.S.S.G. § 5K2.0 (authorizing upward departures if there “exists an aggravating ... circumstance of a kind, or to a degree not adequately taken into consideration by the Sentencing Commission.”).

At resentencing, the district court did make an upward departure. It adopted the findings of the presentence report, which recommended that the base offense level should be twenty with a two level enhancement for role in the offense, and that there should be an upward departure of ten levels. The district court stated that it agreed with the reasons given in the presentence report. The justification for this departure was described by the probation officer as follows:

Rather than calculating a departure score on the basis of the chemical supposition that the substance which Ono attempted to manufacture is approximately 100 times more powerful than heroin, if one concedes that it is at least between 25 and 50 times more powerful, then, granting its heroin equivalent ... the appropriate base level is 32.

The probation officer went on to recommend that the sentence imposed should be at the high end of the range for a base level of 32 because of the considerable scope of the conspiracy.

We review departures from the Guidelines under the three-part test articulated in United States v. Lira-Barraza, 941 F.2d 745 (9th Cir.1991) (en banc). First, this court must determine whether the district court had “legal authority” to depart. This determination is a question of law and is thus reviewed de novo. Second, we review for clear error the district court’s factual findings supporting the circumstance identified as the basis for departure. Last, we must determine whether the extent of the departure is reasonable. Id. at 746-47.

The district court has legal authority to depart upward if it finds that there are aggravating circumstances not adequately considered by the Guidelines. U.S.S.G. § 5K2.0; 18 U.S.C. § 3553(b). Ono contends on appeal that potency is already considered by the Guidelines. As support for this argument, Ono points to the equivalency tables, which are used to determine the base offense level for each listed drug. This argument is meritless because the drug in this case, OPP/ PPP, was not listed. Therefore, the Guidelines considered the potency only of the listed analogue drug. Clearly, the greater potency of OPP/PPP was “not adequately taken into consideration by the Sentencing Commission.”

The illicit drug industry is constantly changing and experimenting to create new “designer drugs.” It is impossible for the Guidelines to list or predict every potential chemical composition that yields a new drug. Appellant’s argument would impose an unnecessary restriction on district courts that is not required by the Guidelines. We refuse to handcuff in this way a district court’s ability to perform justice.

Our second inquiry is whether the departure is supported-by the record. We believe that the district court did not clearly err by *650 relying on the information before it to depart upward. The district court had before it statements by expert witnesses testifying to the strength of OPP/PPP in relation to other drugs. There was also data from scientific journals indicating the extremely potent nature of OPP/PPP when compared to the analogue drugs listed in the Guidelines. Based on this information, we cannot say that the district court clearly erred by finding that OPP/PPP was extremely potent.

The final step in our analysis is whether the departure was reasonable. As to this final prong, we bear in mind that “[rjeversal is required only if the choice is ‘unreasonable’ in light of the standards and policies incorporated in the Act and the Guidelines.” Lira-Barraza, 941 F.2d at 751. The district court should provide an explanation for the extent of departure that is “consistent with other sentences fixed by the Guidelines.” Id. at 749. The reasonableness of this departure is fully supported by the presentence report adopted by the district court.

Appellant Langshaw

Langshaw’s original sentence of 210 months was vacated because the district court failed to address as required by Rule 32 a claim that the presentence report inaccurately included a prior conviction. That defect was cured at resentencing and Langshaw now appeals his new 180-month sentence. He argues in this appeal that the district court erred by denying his request for new counsel. We affirm Langshaw’s sentence.

At trial, Langshaw was represented by Attorney Stanford who was a court-appointed attorney from the Indigent Defense Panel for the Central District of California. After conviction, Langshaw sought new counsel for his appeal.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Abdeljawad
Tenth Circuit, 2019
United States v. Gleason
16 F. App'x 810 (Ninth Circuit, 2001)
United States v. Smith
15 F. App'x 421 (Ninth Circuit, 2001)
United States v. Valerdi-Melgarejo
11 F. App'x 796 (Ninth Circuit, 2001)
United States v. Michael Fisher, AKA Lil Nut
133 F.3d 929 (Ninth Circuit, 1997)
United States v. Andre Miles
107 F.3d 18 (Ninth Circuit, 1997)
United States v. Paul Masaru Ono
103 F.3d 143 (Ninth Circuit, 1996)
United States v. George Paul Salemo
82 F.3d 424 (Ninth Circuit, 1996)
United States v. Phillip J. Robbins
64 F.3d 667 (Ninth Circuit, 1995)
United States v. James B.A. Niven
19 F.3d 31 (Ninth Circuit, 1994)
Ono v. United States
510 U.S. 1063 (Supreme Court, 1994)
United States v. Miguel Angel Martinez-Garcia
15 F.3d 1093 (Ninth Circuit, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
997 F.2d 647, 93 Cal. Daily Op. Serv. 5038, 93 Daily Journal DAR 8543, 1993 U.S. App. LEXIS 15983, 1993 WL 232175, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-paul-ono-united-states-of-america-v-benjamin-langshaw-ca9-1993.